| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Analysts' ratings for Alcon (NYSE: ALC) over the last quarter vary from bullish to bearish, as provided by 10 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 4 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $92.85, a high estimate of $110.00, and a low estimate of $77.53. This current average represents a 8.36% decrease from the previous average price target of $101.32.
The analysis of recent analyst actions sheds light on the perception of Alcon by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Thomas Stephan | Stifel | Lowers | Buy | $85.00 | $90.00 |
| Anthony Petrone | Mizuho | Lowers | Outperform | $110.00 | $120.00 |
| Patrick Wood | Morgan Stanley | Lowers | Equal-Weight | $80.00 | $84.00 |
| Tom Stephan | Stifel | Lowers | Buy | $90.00 | $100.00 |
| Jeff Johnson | Baird | Lowers | Outperform | $95.00 | $108.00 |
| David Adlington | JP Morgan | Lowers | Neutral | $77.53 | $105.88 |
| David Saxon | Needham | Maintains | Buy | $107.00 | $107.00 |
| David Saxon | Needham | Maintains | Buy | $107.00 | $107.00 |
| Larry Biegelsen | Wells Fargo | Announces | Equal-Weight | $93.00 | - |
| Patrick Wood | Morgan Stanley | Lowers | Equal-Weight | $84.00 | $90.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Alcon's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Alcon analyst ratings.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Alcon's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 4.01%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Alcon's net margin excels beyond industry benchmarks, reaching 6.78%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Alcon's ROE excels beyond industry benchmarks, reaching 0.8%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Alcon's ROA stands out, surpassing industry averages. With an impressive ROA of 0.56%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ALC
